retatrutide glp-1 Retatrutide, a GIP, and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA 🎙️ NEW EPISODE: Retatrutide—The Triple

2017;120(1S):S5967

Another study evaluating the 24-week efficacy of oral semaglutide in 25 patients with T2DM aged 2078 years reported preservation of lean mass and appendicular skeletal muscle mass index (ASMI), along with reductions in fat mass

If the patient has both obesity and type 2 diabetes, the provider may be able to prescribe Ozempic for the diabetes indication, and the patient may experience weight loss as a secondary benefit

This includes fruits, vegetables, lean proteins, and whole grains

While more research is always helpful, this suggests that combining approaches may offer added benefit for some women

Certain supplements do appear to influence GLP-1 secretion